Palisade Bio, Inc. - PALI STOCK NEWS

Palisade Bio (NASDAQ: PALI) has announced the European Patent Office (EPO) will publish a patent covering its lead drug, LB1148, on December 22, 2021, offering protection until 2035. This patent strengthens IP protection globally, complementing existing patents in the US and other countries. The company is focused on advancing LB1148 through clinical trials aimed at treating acute and chronic gastrointestinal complications. Previous Phase 2 trials showed LB1148's safety and efficacy, indicating significant improvements in bowel function and reduced ICU stays.

Palisade Bio, Inc. (NASDAQ: PALI) announced the equity grants of options covering 150,000 shares to three new employees under its 2021 Inducement Plan. The grants were made as an inducement for these employees to join the company. Nick McCoy has been appointed as VP of Clinical Operations, bringing extensive experience in conducting clinical studies crucial to Palisade's operations. The options granted will vest over three years, contingent on the employees' continued service. Palisade Bio is advancing therapeutic solutions for gastrointestinal complications and is moving its lead asset, LB1148, towards Phase 3 studies.

Palisade Bio, Inc. (PALI) announced its Q3 2021 financial results and key business updates. The Phase 2 clinical trial showed a significant 1.1-day improvement in GI recovery for patients using LB1148 compared to placebo. A $5.2 million investment from Yuma Regional Medical Center will support LB1148's clinical development. Financially, R&D expenses rose to $624,000, while G&A expenses increased to $2.4 million. As of September 30, 2021, cash and cash equivalents stood at $14.1 million, with outstanding debt of $568,000.

Palisade Bio, Inc. (NASDAQ: PALI) has acquired the NSI-189 asset, a neurogenic compound, through an early exercise option as part of its merger with Seneca Biopharma. This acquisition involves an upfront payment of approximately $400,000, along with potential additional payments of up to $4.5 million based on clinical development milestones. Palisade is focused on developing therapies for gastrointestinal complications, with its lead asset, LB1148, showing promising Phase 2 trial results related to bowel function recovery and reduced hospital stays.

Palisade Bio, Inc. (Nasdaq: PALI) has announced that CEO Tom Hallam, Ph.D. will present at the H.C. Wainwright Global Investment Conference from September 13-15, 2021. The presentation will commence on September 13 at 7:00 AM ET and will be available for investors to view online. Dr. Hallam will also engage in one-on-one meetings during the conference. Palisade Bio is focused on developing therapies for gastrointestinal complications, with its lead asset, LB1148, showing promising results in earlier trials.

Palisade Bio, Inc. (PALI) announced a second quarter business update showcasing positive topline results from a Phase 2 study of LB1148, revealing an accelerated return of bowel function post-surgery. The company entered a worldwide in-licensing agreement with the University of California and received FDA Fast Track Designation for LB1148. Financial results showed R&D expenses decreasing to $314,000 while G&A expenses doubled to $2.4 million. Cash reserves stand at $12.7 million with a debt of $1.1 million, supporting ongoing clinical developments.

Palisade Bio, Inc. announces a $5.2 million investment from Yuma Regional Medical Center at a stock price of $3.45 per share to accelerate the development of LB1148. The investment follows promising Phase 2 clinical data, suggesting LB1148 could become the standard care for gastrointestinal recovery post-surgery. With nearly seven million surgeries annually in the U.S. potentially benefiting, LB1148 aims to enhance patient recovery and reduce healthcare costs. The agreement includes warrants for additional shares and a commitment to register them within 60 days.

Palisade Bio (NASDAQ: PALI) and Newsoara have announced positive topline results from a Phase 2 trial for LB1148, demonstrating a statistically significant 1.1-day acceleration in the return of bowel function in patients after elective bowel resection surgery (p=0.0008). The study involved 120 patients and showed a favorable safety profile, with only 10.9% experiencing drug-related adverse events. The company plans to advance LB1148 to pivotal Phase 3 trials, highlighting its potential to improve recovery times and reduce healthcare costs.

Palisade Bio, Inc. (Nasdaq: PALI) announces an exclusive licensing agreement with the Regents of the University of California to enhance its technology for detecting protease activity in clinical samples. This agreement expands Palisade's proprietary whole-blood assay, crucial for identifying protease activity linked to chronic GI diseases. The company is advancing its pipeline, particularly with its lead asset LB1148, a Phase 3-ready protease inhibitor showing promising results in a Phase 2 trial. This license is anticipated to bolster Palisade's drug discovery capabilities and patient selection during clinical development.